1. Prognostic biomarkers in patients with human immunodeficiency virus-positive disease with head and neck squamous cell carcinoma
- Author
-
Zhang, Hongzheng, Kim, Sungjin, Chen, Zhengjia, Nannapaneni, Sreenivas, Chen, Amy Y, Moore, Charles E, Sica, Gabriel, Mosunjac, Marina, Nguyen, Minh Ly T, D'Souza, Gypsyamber, Carey, Thomas E, Peterson, Lisa A, McHugh, Jonathan B, Graham, Martin, Komarck, Christine M, Wolf, Gregory T, Walline, Heather M, Bellile, Emily, Riddell, James, Pai, Sara I, Sidransky, David, Westra, William H, William, William N, Lee, J Jack, El-Naggar, Adel K, Ferris, Robert L, Seethala, Raja, Grandis, Jennifer R, Chen, Zhuo Georgia, Saba, Nabil F, Shin, Dong M, and Head and Neck Cancer SPORE HIV supplement consortium
- Subjects
Adult ,Male ,Clinical Sciences ,HIV Infections ,Kaplan-Meier Estimate ,Risk Assessment ,survival ,Disease-Free Survival ,Transforming Growth Factor beta1 ,Rare Diseases ,Clinical Research ,Cause of Death ,HIV Seropositivity ,80 and over ,Humans ,2.1 Biological and endogenous factors ,Dental/Oral and Craniofacial Disease ,Aetiology ,Proportional Hazards Models ,Retrospective Studies ,Aged ,Cancer ,Tumor ,human immunodeficiency virus ,Squamous Cell Carcinoma of Head and Neck ,Prevention ,Carcinoma ,biomarkers ,Middle Aged ,Prognosis ,Combined Modality Therapy ,Survival Analysis ,Treatment Outcome ,Logistic Models ,Good Health and Well Being ,Squamous Cell ,Otorhinolaryngology ,Head and Neck Neoplasms ,Case-Control Studies ,Dentistry ,Multivariate Analysis ,HIV/AIDS ,Head and Neck Cancer SPORE HIV supplement consortium ,Female ,head and neck cancer - Abstract
BackgroundWe examined the prognostic value of a panel of biomarkers in patients with squamous cell carcinoma of the head and neck (SCCHN) who were human immunodeficiency virus (HIV) positive (HIV-positive head and neck cancer) and HIV negative (HIV-negative head and neck cancer).MethodsTissue microarrays (TMAs) were constructed using tumors from 41 disease site-matched and age-matched HIV-positive head and neck cancer cases and 44 HIV-negative head and neck cancer controls. Expression of tumor biomarkers was assessed by immunohistochemistry (IHC) and correlations examined with clinical variables.ResultsExpression levels of the studied oncogenic and inflammatory tumor biomarkers were not differentially regulated by HIV status. Among patients with HIV-positive head and neck cancer, laryngeal disease site (P = .003) and Clavien-Dindo classification IV (CD4) counts
- Published
- 2017